Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on May 4, 2021. The filing discloses the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwriting Agreement for the sale of common stock.
- Shares Issued: 26,000,000 shares of common stock.
- Public Offering Price: $1.54 per share.
- Expected Net Proceeds: Approximately $36.4 million (after underwriting discounts and estimated offering expenses).
- Underwriter: H.C. Wainwright & Co., LLC (sole book-running manager).
- Expected Closing Date: On or about May 7, 2021.
Material Changes and Terms
The filing details the financial terms of the offering, including an underwriting discount of 7.5% of gross proceeds and a management fee of 1% of gross proceeds. The Company agreed to reimburse the Underwriter for a non-accountable expense allowance of $50,000, up to $90,000 in legal fees, and $15,950 for clearing expenses. The filing text does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Restrictions
The Company agreed to a lock-up provision, restricting the sale of any common stock or convertible securities for 90 days following the closing of the Offering, subject to limited exceptions and the Underwriter's written consent. The proceeds are intended to support the Company's operations, though specific allocation details are not provided in this excerpt.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received (expected May 7, 2021).
- Confirm the final share count post-offering and any potential dilution impact.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination rights.
- Monitor the Company's use of the approximately $36.4 million in net proceeds.